Drugs / Antihemophilic Factor (Recombinant)
Antihemophilic Factor (Recombinant)
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01599819 | Sep 2011 → Jul 2012 | hemophilia A | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT02932618 | Nov 2017 → Apr 2026 | von Willebrand disease (hereditary or acquired) | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 3 | NCT02210091 | Oct 2014 → Oct 2015 | hemophilia A | Baxalta now part of Shire | Completed | Met primary |
| Phase 42 trials · 1 missed | ||||||
| Phase 4 | NCT00666406 | Mar 2008 → Feb 2009 | hemophilia A | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 4 | NCT00243386 | Jan 2006 → Jun 2010 | hemophilia A | Baxalta now part of Shire | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02973087 Background | Nov 2017 → Jul 2020 | von Willebrand disease (hereditary or acquired) | Takeda | Completed | No outcome recorded |
Press releases naming this drug 8 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antihemophilic Factor (Recombinant) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02973087 ↗ |
| Known as | ADVATE | “OBJECTIVES: To compare the efficacy of two prophylaxis regimens (primary outcome) and of on-demand and prophylaxis treatments (secondary outcome), and to continue the...” PMID 22212248 ↗ Mar 20121“A phase 1 study compared the pharmacokinetic (PK) profile of BAX 855 with that of licensed rFVIII (Advate).” PMID 26157075 ↗ Jul 2015 |
| Known as | Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method | “OBJECTIVES: To compare the efficacy of two prophylaxis regimens (primary outcome) and of on-demand and prophylaxis treatments (secondary outcome), and to continue the...” PMID 22212248 ↗ Mar 2012 |
| Known as | rAHF-PFM | “OBJECTIVES: To compare the efficacy of two prophylaxis regimens (primary outcome) and of on-demand and prophylaxis treatments (secondary outcome), and to continue the...” PMID 22212248 ↗ Mar 2012 |
| Modality | Protein / enzyme biologic | “Recombinant Protein-Free Factor VIII (rAHF-PFM)” NCT00666406 ↗ |
| Route | Intravenous | “Participants will receive rFVIII IV if necessary for OD treatment of breakthrough bleeds or for peri-operative.” NCT02973087 ↗ |